14.05
price up icon0.43%   0.06
pre-market  プレマーケット:  13.97   -0.08   -0.57%
loading
前日終値:
$13.99
開ける:
$13.95
24時間の取引高:
201.07K
Relative Volume:
2.26
時価総額:
$203.39M
収益:
$1.80M
当期純損益:
$1.76B
株価収益率:
0.1184
EPS:
118.674
ネットキャッシュフロー:
$-149.23M
1週間 パフォーマンス:
-1.20%
1か月 パフォーマンス:
+6.04%
6か月 パフォーマンス:
-9.06%
1年 パフォーマンス:
-59.71%
1日の値動き範囲:
Value
$13.53
$14.14
1週間の範囲:
Value
$13.51
$14.64
52週間の値動き範囲:
Value
$10.80
$35.42

Inhibrx Biosciences Inc Stock (INBX) Company Profile

Name
名前
Inhibrx Biosciences Inc
Name
セクター
Healthcare (1165)
Name
電話
(858) 795-4220
Name
住所
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Name
職員
161
Name
Twitter
Name
次回の収益日
2024-05-24
Name
最新のSEC提出書
Name
INBX's Discussions on Twitter

INBX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
INBX
Inhibrx Biosciences Inc
14.05 203.39M 1.80M 1.76B -149.23M 118.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-07-23 開始されました JMP Securities Mkt Perform
2024-01-23 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-03-16 開始されました SMBC Nikko Outperform
2021-09-21 開始されました JMP Securities Mkt Outperform
2021-04-26 再開されました Credit Suisse Outperform
2020-09-14 開始されました Credit Suisse Outperform
2020-09-14 開始されました Evercore ISI Outperform
すべてを表示

Inhibrx Biosciences Inc (INBX) 最新ニュース

pulisher
Apr 01, 2025

Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PR Newswire

Apr 01, 2025
pulisher
Mar 26, 2025

How the (INBX) price action is used to our Advantage - Stock Traders Daily

Mar 26, 2025
pulisher
Mar 18, 2025

JMP maintains Market Perform on Inhibrx stock post-earnings - Investing.com India

Mar 18, 2025
pulisher
Mar 17, 2025

Inhibrx Biosciences, Inc. SEC 10-K Report - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Yahoo

Mar 17, 2025
pulisher
Mar 17, 2025

Inhibrx Cancer Drug Shows Complete Response as Company Posts $1.7B Annual Profit - Stock Titan

Mar 17, 2025
pulisher
Mar 15, 2025

Long Term Trading Analysis for (INBX) - Stock Traders Daily

Mar 15, 2025
pulisher
Mar 04, 2025

When (INBX) Moves Investors should Listen - Stock Traders Daily

Mar 04, 2025
pulisher
Feb 17, 2025

A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News

Feb 17, 2025
pulisher
Feb 11, 2025

When the Price of (INBX) Talks, People Listen - Stock Traders Daily

Feb 11, 2025
pulisher
Feb 05, 2025

BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com

Feb 05, 2025
pulisher
Jan 31, 2025

(INBX) Trading Signals - Stock Traders Daily

Jan 31, 2025
pulisher
Jan 23, 2025

Inhibrx reports promising ozekibart trial results - MSN

Jan 23, 2025
pulisher
Jan 23, 2025

Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN

Jan 23, 2025
pulisher
Jan 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 - GuruFocus.com

Jan 21, 2025
pulisher
Jan 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer – Company Announcement - Financial Times

Jan 21, 2025
pulisher
Jan 21, 2025

Inhibrx's Ozekibart Shows Promising 40% Response Rate in Advanced Colorectal Cancer Trial - Stock Titan

Jan 21, 2025
pulisher
Jan 20, 2025

How to Take Advantage of moves in (INBX) - Stock Traders Daily

Jan 20, 2025
pulisher
Jan 14, 2025

Inhibrx Biosciences enters $150M loan facility - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan - Endpoints News

Jan 14, 2025
pulisher
Jan 13, 2025

Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com

Jan 13, 2025
pulisher
Jan 13, 2025

Inhibrx Secures $150M Financing Deal to Advance Clinical Programs, Receives $100M Upfront - Stock Titan

Jan 13, 2025
pulisher
Jan 10, 2025

(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Jan 10, 2025
pulisher
Dec 30, 2024

How To Trade (INBX) - Stock Traders Daily

Dec 30, 2024
pulisher
Dec 17, 2024

Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com India

Dec 17, 2024
pulisher
Dec 09, 2024

(INBX) Trading Report - Stock Traders Daily

Dec 09, 2024
pulisher
Dec 05, 2024

Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Nigeria

Dec 05, 2024
pulisher
Dec 05, 2024

Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com

Dec 05, 2024
pulisher
Dec 02, 2024

2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - News & Insights

Dec 02, 2024
pulisher
Nov 22, 2024

Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Nigeria

Nov 22, 2024
pulisher
Nov 18, 2024

Trend Tracker for (INBX) - Stock Traders Daily

Nov 18, 2024
pulisher
Nov 17, 2024

The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance

Nov 17, 2024
pulisher
Nov 17, 2024

institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St

Nov 17, 2024
pulisher
Nov 15, 2024

Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire

Nov 14, 2024
pulisher
Nov 12, 2024

Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 09, 2024

Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com

Nov 09, 2024
pulisher
Nov 07, 2024

Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle

Nov 07, 2024
pulisher
Nov 05, 2024

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha

Nov 05, 2024
pulisher
Nov 04, 2024

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - Financial Times

Nov 04, 2024
pulisher
Oct 25, 2024

James Sabry on industry-shaping changes in innovation and deal-making - BioCentury

Oct 25, 2024

Inhibrx Biosciences Inc (INBX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
大文字化:     |  ボリューム (24 時間):